COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY

Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHRISTIN TSE, STEPHEN KENNETH TAHIR, PAUL E. KROEGER, JOHN A. WASS, SAUL HOWARD ROSENBERG, MARK GERALD ANDERSON
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ENZYMOLOGY MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MUTATION OR GENETIC ENGINEERING PROCESSES OF PREPARING SUCH COMPOSITIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy. Se describen métodos para identificar pacientes con cáncer elegibles para recibir la terapia del inhibidor de la familia Bcl-2 y para supervisar la respuesta del paciente a la terapia del inhibidor de la familia Bcl-2, que comprende la evaluación de los niveles de expresión del conjunto de combinaciones del marcador biológico en las tablas 1, 2, 3, 4, 5, ó 6 en una muestra de tejido del paciente. Los métodos de la invención permiten más eficiencia en la identificación de pacientes para recibir la terapia del inhibidor de la familia Bcl-2 y de la determinación de la respuesta del paciente a la terapia.